Get a glimpse into our company and investor data—powered by the PitchBook Platform
VM Pharma (TrkA Program)
Asset Purch.LATEST DEAL TYPE
VM-902A pharmaceutical product. The asset is used to develop VM-902A which is orally bioavailable, peripherally acting and allosteric selective tropomyosin receptor kinase for recovering of many diseases in USA.